šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT Ā· Real-Time Price Ā· USD
1.660
+0.070 (4.40%)
At close: Nov 20, 2026, 4:00 PM EST
1.630
-0.030 (-1.81%)
After-hours: Nov 20, 2026, 7:49 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

Clinical plans target 2027 entry for VLR199 and VLR360, with proof-of-concept data targeted for 2028. The pipeline spans PAH, HFpEF and lung diseases, supported by $350M in financing and runway into 2029.

Michael Henderson
President, Velaris

Great to be here. Appreciate everyone, especially the early morning slot. They are real go-getters. Excited to tell you about Velaris today. There we go. I will be making forward-looking statements. Velaris was set up out of Paragon to develop a pipeline of drugs going after pulmonary hypertension and related cardiopulmonary diseases. When you look at PAH, or pulmonary arterial hypertension, significant unmet need, mortality, like survival curves, one mechanism really has risen to the top. That is activin signaling. One drug, sotatercept, or now Winrevair, has launched very well over the past few years. This was Acceleron acquired by Merck, and it has launched incredibly well, which we will get into in a moment. Nothing else has really come behind this as a second-in-class mechanism. What we are doing is we are advancing quickly, something that phenocopies sotatercept, to go quickly into PAH.

We will be in the clinic next year with phase I-B proof of concept data, which is very nice and dose-dependent. It should be quite reified. We are bringing a number of next-gen approaches as well, VLR247 and VLR258, which bear BMP9/10, and we will get into the biology of that in a bit. We are the first company to also be bringing combinations to this space, so PDGFB. We are advancing to the clinic next year. We will look to this as a potentially best-in-class mono, and also the first-in-class combination approach in PAH. Outside of PAH, I think is where the story gets quite interesting as well. We will be looking at heart failure, so specifically HFpEF, where sotatercept just put up very strong, hazard ratio of less than 0.2 data in phase II, and they are now moving to phase III.

We look to be first in class across five or so different pulmonary indications, all which have blockbuster potential, and we will have first mover advantage there. This is data which I think many people might have actually missed, which is within Merck, sotatercept is off to a very strong launch. So $2 billion two years in. I think this is one of the more under-the-radar launches out there, and it is looking to do $8 billion-$10 billion in PAH alone. When we compare PAH on the left to the other indications where sotatercept and activin signaling could be employed, I think this tells a story of how this could be one of the larger classes out there, again, under the radar. PAH, 30,000-50,000 patients, $8 billion peak.

The cardiac indication, pulmonary hypertension of heart failure with preserved ejection fraction, what is called HFpEF for short, about 10 times as many potential patients in that indication. Merck just put out phase II proof of concept data showing a hazard ratio of 0.18, which is kind of unheard of these days in any heart failure study. So they are now moving that into phase III, just the lower dose. We think room to improve on the dose there. In respiratory indications, there has been a number of different PAH drugs with less efficacy that have transitioned from PAH into interstitial lung disease, PH-COPD, IPF, PPF. Nobody has tried formally to take an activin drug into those indications. We look to be the first movers. We will get into some of the anecdotal and clinical evidence out there from doctors that are doing this already, putting out quite compelling data.

This just shows the lung and the heart are connected. Pulmonary vascular remodeling does happen due to imbalanced growth signaling, and this is why outside of just group one, which is pulmonary arterial hypertension, this mechanism also works in group two and group three diseases. Group two being left-sided heart failure, that HFpEF we talked about, and group three being interstitial lung diseases, ILD, IPF, COPD, et cetera. Activin signaling just rebalances the growth, so you make the vessel much more patent and able to deliver blood and therefore transport oxygen. Our lead program, VLR199, as you can see on the left, it rebalances the proliferative and anti-proliferative mechanisms to reopen that blood vessel and allow for oxygen to be carried more effectively. On the right, you can see how we compare to Winrevair or sotatercept in our preclinical studies.

You can see that we very closely pharmacomimetic Winrevair's mechanism of action, giving us confidence to take this drug aggressively forward. Outside of PAH, where we will look to improve upon what sotatercept does in terms of dosing, delivery, and a number of other factors with our clinical strategy in PAH, we are going to move aggressively into HFpEF, where we can be a fast follower. Merck, they relied on their PAH dosing, and we think that there's room to improve as their top dose did not deliver, and only the lower dose is currently being taken forward. It is in phase III, though, very, very impressive results, but we'll look to see if we can optimize dosing further, and then be first in class in PH-ILD and additional opportunities like COPD, IPF, PPF.

These are the sorts of indications, where 20, 30 billion dollar biotechs have recently launched drugs, and we think the efficacy here could be quite profound. What's really nice about PAH is that you can move quite rapidly, and there are precedent data that we can rely on to get very quick proof of concept. You can see here, going from left to right, phase I, II, and III. The phase I, we will run a SAD, and we'll look for a dose-dependent biomarker where we'll look to replicate what sotatercept has done. We'll then do phase IIs in PAH, HFpEF, and the lung diseases, which can then quickly go to registrational studies. Very nice regulatory precedent here, and the unmet need is still incredibly high in these patients. So, plenty of appetite out there globally for these indications and to get these trials enrolling.

This is just that phase I data, which will be really the first data that we put on the board after we get into the clinic next year. Some phase Is, you look to prove that it's safe, and then you move forward into phase II. I think here, there is a very clear dose-dependent biomarker, serum FSH, and we're showing sotatercept's data, or Winrevair on the left. We'll look to replicate this with our phase I data, giving us confidence and informing the doses that we then take into phase II. We'll also look for hemoglobin changes and other biomarker changes closely linked with activin signaling. Following the phase I, our phase II will look to optimize the dose. These can be pretty tight studies, right? Talking 100 to 150 patients, so pretty seamless.

Then we will go into a phase III design, where again, regulatory pathways are quite clear, approval precedent, and six-minute walk duration. Beyond PAH, I think, is where there is significant upside and where you will see us focus a lot of our story, because again, heart failure, roughly 10 times the number of patients. The Merck data was quite impressive, and I think a lot of room to improve for options for patients in this space. Then across lung disease, right? Interstitial lung, COPD, IPF, PPF, these are all ILD is the closest in terms of PAH is 50,000 patients, ILD 60,000-70,000. The others are obviously much larger. So, each a potential blockbuster indication where docs are already using this, and we will get into that data shortly. This is the heart failure data that I mentioned.

You can see the PAH data for sotatercept on the left with a hazard ratio of 0.16. Again, right, these are trials that end up getting paused early because equipoise demands that the drug be approved faster. On the right, you can see the heart failure data of 0.18 that Winrevair delivered just earlier this year. Again, at that lower 0.3 mg per kg dose, the 0.7 actually looked worse. So we think room to potentially improve there. They are advancing into phase III and will look to be a fast follower. A number of PAH drugs have gone from PAH into ILD and pulmonary fibrosis with remarkable success, despite having more limited PAH data. So we are excited to take the most active PAH drug into these diseases and see what we can do. Two examples that I think will just be familiar for investors.

United, of course, with Tyvaso, prostacyclin. It does achieve stat sig in PAH, but is nowhere near as effective as sotatercept. Two positive IPF phase IIIs just read out, following an ILD phase III. They are doing a few billion in these indications. Roivant, of course, took a drug that had been shelved for PAH and reported a few months ago positive phase II data, leading to a pretty nice market reaction, and they are now moving quickly into phase III. We would expect to do something similar. A bit more around kind of the signal that has been seen in these lung diseases. A bit of a complicated slide, but in gray is sotatercept PAH data. You can contrast that with the standard of care, treprostinil, in orange. You can see that on six-minute walk and BNP, you see a very nice improvement for sotatercept versus inhaled prostacyclins.

Then you can see that docs have, of course, noticed this, and they have tried this in their patients in a number of different case reports in group three lung diseases. The first kind of lime green from Patel, then the darker green from Dogar. You can see heretofore unseen changes in six-minute walk duration in group three patients. Really nice improvements in PVR, which would be expected given the mechanism of sotatercept, and very nice changes in BNP as well. So this is not just a hypothesis, but docs are actually doing this given that they have used these patients before, used different PAH drugs in ILD, and seen really nice results. Beyond kind of our lead program and moving aggressively into the group one, two, and three diseases, we are trying a few next-generation approaches as well.

We structured this company so that whatever mechanism that anybody is trying in PAH, we want to be the winner. We built in a number of different call options into the company, because if sotatercept can be improved upon, we want to be the ones to do it. Two distinct approaches that we're taking beyond our lead 199 are VLR247 and VLR258. Here, we've dialed out BMP9 and 10 signaling. It gets a bit complicated, but BMP9 and 10 lead to hemoglobin increases, and they limit the amount of efficacy that can be achieved with sotatercept because they limit the dose. You really want to hit activin A and B hard, but you can only do so much without changing too much hemoglobin and BMP9 and 10. People have tried to go after this and do it.

GSK acquired a company earlier this year, 35Pharma, that is currently in phase II in both PAH and HFpEF, that heart failure indication. That data's coming next year. If that data's positive, then we will be positioned quite well to move forward our VLR258 and VLR247 into the same indications where GSK is playing, potentially able to push the dose without worrying about those side effects. If that does not read out positively, then we will continue forward with 199 as planned. Additionally, there emerging work on PDGFB. This stems from a really impressive dataset that imatinib, which is, of course, GLEEVEC, a cancer drug produced in PAH, where it showed similar efficacy data, almost as profound as sotatercept, with an orthogonal mechanism. Of course, imatinib does carry tox, so close to 30% dropout rate despite that really nice efficacy benefit.

It was not carried forward given the efficacy safety equipoise was not there. However, it's thought to be that PDGFB was the primary driver of that efficacy. Regeneron is currently in phase II with a PDGFB selective antibody. We are coming into the clinic next year with a half-life extended antibody against PDGFB, so we can improve upon their dosing and look to develop this not only as a monotherapy on their heels, but we would be uniquely positioned to combine this with our lead, and we have engineered these to be co-formulatable. So quite excited to see that readout, and if there is safety that does not overlap with SOTA, as well as a modicum of efficacy, even anything incremental, we would look to be first in class combining it in PAH and also consider additional indications. This just shows the mechanisms a bit more.

Activin signaling is on the left. It really is a pro-proliferative mechanism, so decreasing that with an activin inhibitor leads to just less proliferation and kind of opening up those blood vessels. PDGFB signaling, it hits a number of things, really cell growth, survival, and remodeling, so a really nice orthogonal mechanism to try out. As mentioned, we have designed this with combination in mind, so that we can co-formulate these and look at these quickly in a phase II proof of principle. Next year is going to be a very exciting year for us as we enter the clinic with our lead program, 199, and also 360. That's the anti-PDGFB antibody. We'll be getting our proof of concept data for both of those then in the 2028 timeframe.

I think along the way, what's going to be exciting as well is there's going to be external data from first-generation molecules. Merck's Winrevair will continue to produce data. Docs will continue to use it, I'm sure, in published case studies across group three diseases, which we'll be closely watching to inform our own studies. GSK is advancing, again, their BMP9/10 sparing drug with data coming in PAH next year, and then HFpEF in 2028, which we'll be keenly watching. Regeneron with their phase II data in 2028 in PAH. Lastly, the team, you can see us here. Most of us recently came over from Apogee Therapeutics, heard of this opportunity, and got quite excited. Thank you.

Speaker 2

Awesome. Thanks, Michael. I think maybe the first question I wanted to ask that I feel like is a line of questioning you've been used to in the past is sort of, why can't Merck look at your plan here for VLR199 and sort of just do the same thing with sotatercept? What's been the inertia there to prevent them from going back and sort of fixing some of the historical issues and maybe thinking about lung disease too?

Michael Henderson
President, Velaris

Yeah. I think that if pharma were rational, biotech wouldn't exist.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

Not the first time kind of encountered that situation. If you look at the history of sotatercept, it had a long clinical development history and eventually proved itself incredibly effective.

in PAH. If you look back at kind of how they landed on their dosing, right, I think if you talk to people that were involved in that, it was not fully optimized.

Right? It is the only Q3 week drug, by and large, that I am aware of that is approved.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

I think that they landed on that kind of after a number of indication pivots.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

Eventually landed on PAH. I think Merck, when they acquired Acceleron, right, they looked to get that drug approved as quickly as they could, and it was already in flight with that dosing.

To change it would have been a step back, and steps back cost time and money.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

They took it forward aggressively, and then I think the heart failure data really shows that, right, even if within PAH, they have an interesting dose within heart failure.

Speaker 2

Yeah

Michael Henderson
President, Velaris

They only take the low one forward, and now as they think about other pressures like IRA, it is kind of just too late for them to go into group three diseases. They have to do a phase II, and they have to do phase IIIs, and you are talking IRA about nine years from now for them, which is, right, a SOTA problem, not an us problem.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

Being first in class in these lung diseases, in particular, I think it is just a moment in time.

Speaker 2

Yep. Yeah, maybe can you unpack a little bit more around the specific dose ranging data or that sort of process that was done and sort of where you see the potential for gaps that you can optimize around beyond just Q3 week dosing?

Michael Henderson
President, Velaris

Yeah, so SOTA is a 0.3 to 0.7 mg per kg titration. That came out of a phase I-B in post-menopausal women when sotatercept, which is an anabolic mechanism, was being studied for osteoporosis. There were hemoglobin changes above that, but it was never then kind of, they said that they did modeling, et cetera, and then kind of just fell back into, let's go with the 0.3 and the 0.7 because above that at different dosing frequencies—

100 days past the last dose, there was a heme change.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

They settled on it. Obviously, it worked quite well in PAH. If you look at the phase II data in PAH, I think PVR, which is pulmonary vascular resistance, did show a nice dose-dependent change.

None of the other endpoints really did. They actually looked pretty flat.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

You do see more AEs at the 0.7 mg/kg dose. So, I think it's obviously an incredible drug.

Speaker 2

Sure.

Michael Henderson
President, Velaris

Docs love it. If you asked docs, "Do you think that the dosing is nailed and that patients love an every three-week schedule, or do you love an every three-week schedule?" That's vial syringe that requires math to figure out what to give each patient. They recognize that a class of this size with this much market potential—

improvements could be made.

Speaker 2

Is ultimately the goal to get to maybe some sort of flat dosing with a subcu auto-injector first Q4 weekly profile? Is that kind of broad strokes what you are looking for?

Michael Henderson
President, Velaris

Yeah, I think that could be a likely outcome.

It would probably be more weight bands.

Speaker 2

Okay.

Michael Henderson
President, Velaris

But try to make it easy for everyone.

Speaker 2

Yep. Then, maybe I think the other question here too is sort of like, when you are thinking about 9/10 sparing in particular with the second-gen asset, we talked about what happened, the progression of the GSK now, the now GSK asset, but I think Keros is the other story that people might see and sort of get worried about

the ability to achieve that level of selectivity. So can you walk through maybe what the learnings were from Keros and how you are approaching this question?

Michael Henderson
President, Velaris

Yeah. We are fortunate that there has been a number of successes and failures that we are able to learn from in this space. Yeah, I think Keros and even 35Pharma's lead drug both kind of experienced setbacks in the clinic that were surprising to folks. I think hindsight is 20/20, of course, so it is super easy to sit here now and sound smart about it. But if you look at the Keros drug, they did spare BMP9, but they actually spared everything.

Right? So they also spared activin signaling. So to get to the same activin inhibition that is achieved with sotatercept, they actually ended up, you have to dose to a level that you hit BMP9 and 10 both harder than sotatercept does. And you can see that kind of in their past dose, and it is also evident just in their phase II data. Not only was safety not favorable, but efficacy was not favorable either.

I think that it was an interesting hypothesis with a flawed molecule.

Speaker 2

Yep.

Michael Henderson
President, Velaris

I think with GSK's drug, it does spare BMP9 and 10 a bit. We'll see what that delivers. I think the reason why we are a bit reserved on making predictions is improving your hemoglobin—

Speaker 2

Yeah

Michael Henderson
President, Velaris

increasing it, which is on target for sotatercept, it's not the worst thing. Sotatercept's like an anti-doping—

for bikers. I'm sure you're on it, Alex. But it's like taking EPO.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

It does improve your six-minute walk duration potentially, and you can get very smart scientists who will, right, like have a knife fight about whether or not you want to spare BMP9/10. Our view is we're going to have both, so if it does work

and you can spare it and push efficacy, great. We'll be ready to kind of quickly go into it. If no, it looks like that's actually a feature, not a bug, then full steam ahead with our lead.

Speaker 2

Then maybe I wanted to talk a little bit more about thoughts around commercial dynamics, particularly with HFpEF versus PAH and the smaller specialty markets. Is your expectation that with the lower dosing, the price, there will be a significant price differential between HFpEF and PAH? Is that the way that this probably shakes out or no?

Michael Henderson
President, Velaris

Not based off of what Merck's saying. I think that Merck is, they're very focused, which makes sense, on retaining kind of orphan status.

Speaker 2

Yep.

Michael Henderson
President, Velaris

I think that they're going to tailor, make the argument that their label and their inclusion/exclusion criteria for their ongoing HFpEF study matches orphan, and there is flat pricing between the 0.3 and 0.7.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

They're going to, I think, maintain that high price. And given a hazard ratio of 0.18 when, right, we're seeing myriad heart failure drugs just-

be unsuccessful with hazard ratios of 0.99, they're going to have a pretty strong argument to be able to push that.

Speaker 2

I think the other interesting question in this space is obviously the morbidity and mortality is quite high. If VLR199 is out in the market, you're improving tolerability, dosing, and convenience. Is this a switch market or is this more of an incident market dynamic for you over time?

Michael Henderson
President, Velaris

Yeah. I think it could be both.

Fortunately, mortality curves are improving

on sotatercept. I think that when you start to see patients just get better controlled, then be on a drug for quite some time, sometimes they will be unwilling to switch because

Speaker 2

Yeah

Michael Henderson
President, Velaris

why rock a boat if it is working? I think a lot of them too, especially if it is the same mechanism.

Speaker 2

Yeah

Michael Henderson
President, Velaris

they can get comfort with that. As we think about combinations and pushing that even further

right, layering on another mechanism when they're already achieving benefit from something, I think would be

Speaker 2

Yeah

Michael Henderson
President, Velaris

a proper, just a pretty normal path.

Speaker 2

This is already very much a polypharmacy indication, right?

Michael Henderson
President, Velaris

Yeah. These docs, I mean, they layer on mechanisms, right? Like, you are on a vasodilator, vasoconstrictor, you end up on ACEs, ARBs, everything because, right, they historically have kind of thrown the kitchen sink at these very sick patients to try to control their hemodynamics.

Speaker 2

You mentioned this a little bit, as a biotech versus Merck, can you talk a little about this being a Medicare population and the sort of pros and cons versus being a biotech versus a large pharma there?

Michael Henderson
President, Velaris

Yeah. I mean, right, these are the sorts of indications and unmet needs where you can rapidly get access. It is a very concentrated prescriber base, so you can, I think, launch quite well without needing. This is not a primary care space.

You have specialists that really treat these, that follow the literature, and are looking right now for the best commercials, but just the best data. I think that we will be able to, right, if we produce data that is compelling, rapidly gain share.

Speaker 2

Yep. Then maybe, can you walk through what is left from an IND-enabling perspective to get into the clinic across VLR199 and VLR360 at this point?

Michael Henderson
President, Velaris

Just all the operations.

Speaker 2

Yep.

Michael Henderson
President, Velaris

You know, all the boring stuff.

Speaker 2

Okay.

Michael Henderson
President, Velaris

So, right, we know what to expect with tox. We are just running our tox studies.

We'll advance into the clinic. We know what to expect from SOTA, right? There is tox, so it's more about just establishing what entry dose you get into the clinic with.

Speaker 2

Yeah.

Michael Henderson
President, Velaris

Setting it up for success with that dose-dependent FSH change.

Speaker 2

Yeah. Maybe the other thing to cover here is just your position as the president here and your position at Paragon and your expectations around running Velaris over time. How are you framing that?

Michael Henderson
President, Velaris

Yeah. We've been very clear with investors on this. Also CEO of Paragon as part of that, right? Paragon creates companies like Velaris. You'll see other companies come out of Paragon over the next year. Coming out of this, what we had done in Apogee, where I was before, is we had kind of understood what capabilities Paragon was great at and then kind of built a team to then translate those rapidly into the clinic and achieve POC. So, a good portion of that team is now ported over. We have the executive team, which we announced about a month ago, alongside the Velaris financing.

We will be setting it up for success with that team, and then within the first year, we will look to find a permanent CEO that will come in, and then I will be on the board, a very annoying board member, I am sure.

We will continue to support it via Paragon, but install a more permanent management team.

Speaker 2

Then maybe finally, with the financing, what does your runway look like?

Michael Henderson
President, Velaris

Yes, into 2029. We set out to raise $200 million. We ended up upsizing that due to demand to $350 million. That gives us the ability to kind of achieve all the data that you saw on that slide, and with runway into 2029, which is a great position to be in in these fund markets.

Speaker 2

Great. Any final thoughts?

Michael Henderson
President, Velaris

Thank you for the

Speaker 2

Awesome

Michael Henderson
President, Velaris

opportunity to be here.

Speaker 2

Thanks, Michael. Appreciate it.

Michael Henderson
President, Velaris

Thanks.